D
David Venzon
Researcher at National Institutes of Health
Publications - 436
Citations - 28417
David Venzon is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Simian immunodeficiency virus & Virus. The author has an hindex of 93, co-authored 423 publications receiving 26502 citations. Previous affiliations of David Venzon include Rush University Medical Center & University of Würzburg.
Papers
More filters
Journal ArticleDOI
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Austin G. Duffy,Susanna Varkey Ulahannan,Oxana Makorova-Rusher,Osama E. Rahma,Heiner Wedemeyer,Drew Pratt,Jeremy L. Davis,Michael S. Hughes,Theo Heller,Mei ElGindi,Ashish Uppala,Firouzeh Korangy,David E. Kleiner,William D. Figg,David Venzon,Seth M. Steinberg,Aradhana M. Venkatesan,Venkatesh Krishnasamy,Nadine Abi-Jaoudeh,Elliot Levy,Brad Wood,Tim F. Greten +21 more
TL;DR: Tremelimumab in combination with tumor ablation is a potential new treatment for patients with advanced HCC, and leads to the accumulation of intratumoral CD8+ T cells, with a possible surrogate reduction in HCV viral load.
Journal ArticleDOI
Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.
Mario Clerici,Frances T. Hakim,David Venzon,Stephen P. Blatt,Craig W. Hendrix,Thomas A. Wynn,Gene M. Shearer +6 more
TL;DR: The results suggest that the TH functions assessed by IL-4 production replace the normally dominant TH function of antigen-stimulated IL-2 production in the progression toward AIDS, and raise the possibility of cytokine cross-regulation in AIDS therapy.
Journal ArticleDOI
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Ian Magrath,Melissa Adde,Aziza T. Shad,David Venzon,Nita L. Seibel,J Gootenberg,J. Neely,C Arndt,M. Nieder,Elaine S. Jaffe,R. A. Wittes,I D Horak +11 more
TL;DR: EFS in high-risk patients has been markedly improved by including IVAC in protocol 89-C-41, and excellent results can be achieved with only four cycles of therapy, and GM-CSF was not beneficial.
Journal ArticleDOI
Determinants of Metastatic Rate and Survival in Patients With Zollinger-Ellison Syndrome: A Prospective Long-term Study
H. Christian Weber,David Venzon,Jaw-Town Lin,Vitaly A. Fishbein,Murray Orbuch,Doris B. Strader,Fathia Gibril,David C. Metz,Douglas L. Fraker,Jeffrey A. Norton,Robert T. Jensen +10 more
TL;DR: Survival was primarily determined by the presence of liver metastases, and the frequency of Liver metastases depends on the size and location of the primary tumor and on the Presence of MEN-1 at the initial presentation.
Journal ArticleDOI
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
Claude Sportes,Frances T. Hakim,Sarfraz Memon,Hua Zhang,Kevin S. Chua,Margaret R. Brown,Thomas A. Fleisher,Michael Krumlauf,Rebecca Babb,Catherine Chow,Terry J. Fry,Julie Engels,Renaud Buffet,Michel Morre,Robert J. Amato,David Venzon,Robert Korngold,Andrew L. Pecora,Ronald E. Gress,Crystal L. Mackall +19 more
TL;DR: It is suggested that rhIL-7 therapy could enhance and broaden immune responses, particularly in individuals with limited naive T cells and diminished TCR repertoire diversity, as occurs after physiological (age), pathological (human immunodeficiency virus), or iatrogenic (chemotherapy) lymphocyte depletion.